Coronavirus Update: US Adds To Antibody Push With $486m AstraZeneca Deal
Plus: Bharat To Start Phase III Vaccine Trials Shortly
Executive Summary
After a week of monoclonal antibody therapies hitting the headlines - including a personal endorsement from President Trump - the US government bulks up its potential supplies. AZ's long-acting monoclonal antibody product enters large-scale trials for both a treatment and prophylaxis of COVID-19.
You may also be interested in...
AZ’s ‘Long Shot’ COVID-19 Trial Of Diabetes Drug Farxiga Fails
The failure of the SGLT2 inhibitor is not unexpected, but allays any concerns that it could have worsened outcomes for patients with hypertension or heart disease.
Waters Muddied As Bharat Readies COVID-19 Vaccine For '21 Launch
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Coronavirus Update: Praised By Trump, Regeneron Files Antibody Cocktail For Emergency Use Authorization
Trump's praise of the therapy and talk of a 'cure' for COVID-19 has raised concerns about misinformation and pressure on the US FDA once again.